证券代码：000623 证券简称：吉林敖东 债券代码：127006 债券简称：敖东转债 吉林敖东药业集团股份有限公司 投资者关系活动记录表 编号：2023-018 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活 □新闻发布会 √路演活动 动类别 □现场参观 □其他（请文字说明其他活动内容） 现场方式 参与人员及方 天风证券：张中华 式 华泰保险：王金成 时间 2023年11 月2日 地点 长沙世茂希尔顿酒店 上市公司接待 董事、副总经理：杨凯 人员姓名 董事、副总经理、董事会秘书：王振宇 1、公司简介 由董事、副总经理、董事会秘书王振宇先生从企业沿革、 主营业务、经济指标、产品构成、投资、大健康领域、未来规 划等方面介绍公司基本情况，详情可查阅公司定期报告及本年 度之前披露的投资者关系活动记录表。 2、在公司中药产品构成方面，除了老品种安神补脑液外， 是否有什么发展比较好的新产品？ ...

| 证券代码：000623 | 证券简称：吉林敖东 | 公告编号：2023-075 | | --- | --- | --- | | 债券代码：127006 | 债券简称：敖东转债 | | 吉林敖东药业集团股份有限公司 关于回购部分社会公众股份进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 吉林敖东药业集团股份有限公司（以下简称"公司"）于2023年9月20日召 开公司第十一届董事会第三次会议、第十一届监事会第三次会议，审议通过了《关 于回购部分社会公众股份的议案》，同意以自有资金不少于人民币1.00亿元（含）， 不超过人民币1.50亿元（含）回购部分社会公众股份，回购股份全部用于员工持 股计划，回购价格不超过人民币20.00元/股。根据本次回购价格上限测算，本次 拟 回 购 股份 数量 上 限为 750 万股 ， 即不 超 过公 司 2023年 6月 30 日总 股 本 1,163,105,155股的0.64%；下限为500万股，即不低于公司2023年6月30日总股本 1,163,105,155股的0.43%。回购股份实施期限为自公司董事会审议通过 ...

Company Overview - Jilin Aodong Pharmaceutical Group Co., Ltd. operates under a multi-wheel drive model of "Pharmaceuticals + Finance + Health" and adheres to the business philosophy of "World Health, Aodong Responsibility" [2] - As of September 30, 2023, the company reported total assets of CNY 32.168 billion, an increase of 3.19% from the beginning of the year [2] - The net assets attributable to shareholders reached CNY 10.02 billion, growing by 3.85% [2] Financial Performance - The company's net profit for the first three quarters of 2023 was CNY 1.274 billion, a year-on-year increase of 44.72% [2] - The asset-liability ratio stood at 15.01% [2] - The company has maintained a continuous profit for several years, with a net profit exceeding CNY 1 billion [2] Business Segments Pharmaceutical Sector - The pharmaceutical business includes traditional Chinese medicine, chemical drugs, and retail pharmacy operations [3] - In the first three quarters, the company achieved sales revenue from 2 products exceeding CNY 100 million and 24 products exceeding CNY 10 million [3] - The sales growth rate for the "Nerve and Heart Comfort Oral Liquid" reached 146.69% year-on-year [3] Health Sector - The health segment produced over 200 types of health functional foods and dietary supplements in 2023, with 22 health food registration certificates and 76 filing certificates [3] - Five products in this segment achieved sales revenue exceeding CNY 10 million, with over 30 products exceeding CNY 1 million [3] Financial Investment - The financial investment segment includes a significant stake in GF Securities, with the company holding 1,252,297,867 A-shares and 213,702,600 H-shares, totaling 19.7199% of GF Securities' total share capital [3] - The company has conducted multiple share buybacks, investing CNY 570 million to repurchase 36,158,251 shares [4] Strategic Initiatives - The company has completed the listing of 368 varieties of traditional Chinese medicine formula granules, enhancing its market competitiveness [5] - A project for traditional Chinese medicine formula granules is expected to generate annual sales revenue of CNY 1.262635 billion and an average annual profit of CNY 234.9227 million [5]

Financial Performance - The company's operating revenue for Q3 2023 was ¥770,811,425.42, representing a 16.33% increase compared to the same period last year[16]. - The net profit attributable to shareholders for Q3 2023 was ¥211,091,832.95, a decrease of 45.29% year-on-year[16]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥233,729,049.33, an increase of 13.27% year-on-year[16]. - Basic earnings per share for Q3 2023 were ¥0.1873, down 44.94% from ¥0.3402 in the same period last year[16]. - The net profit attributable to the parent company was CNY 1,274,274,099.10, representing a 44.72% increase compared to CNY 880,489,963.14 in the previous period[36]. - The total comprehensive income attributable to the parent company was CNY 1,387,040,007.51, compared to CNY 932,518,878.43 in the previous period[36]. - Basic earnings per share increased to CNY 1.1307 from CNY 0.7744, reflecting a significant improvement in profitability[36]. - The total comprehensive income for the period was CNY 1,382,791,406.54, compared to CNY 939,120,648.91 in the previous period, indicating overall growth[36]. - Net profit for the current period was ¥1,270,025,498.13, a significant increase of 43.1% from ¥887,091,733.62 in the previous period[44]. - The profit attributable to shareholders of the parent company was ¥1,274,274,099.10, compared to ¥880,489,963.14, marking a growth of 44.8%[44]. Cash Flow - The net cash flow from operating activities for the year-to-date was -¥284,949,974.74, indicating a significant decline of 732.64% compared to the previous year[16]. - Cash flow from operating activities showed a net outflow of CNY 284,949,974.74, a decrease from a net inflow of CNY 45,041,314.39 in the previous period, indicating reduced cash receipts from sales[36]. - The net cash flow from investment activities was $1.04 billion, recovering from a negative $63.05 million in the previous period[47]. - The net cash flow from financing activities was -$336.81 million, worsening from -$212.95 million last year[47]. - The net increase in cash and cash equivalents was $420.15 million, contrasting with a decrease of $235.55 million last year[48]. Assets and Liabilities - Total assets as of September 30, 2023, were ¥32,167,765,354.95, reflecting a 3.19% increase from the end of the previous year[16]. - The equity attributable to shareholders increased by 3.85% to ¥27,038,805,418.21 compared to the end of the previous year[16]. - The total assets of the company reached approximately CNY 32.17 billion, an increase from CNY 31.17 billion in the previous period, reflecting a growth of about 3.2%[41]. - Non-current assets totaled approximately CNY 25.94 billion, up from CNY 25.19 billion, indicating an increase of around 2.9%[41]. - The company's total liabilities include accounts payable of approximately CNY 398.17 million, down from CNY 436.81 million, showing a decrease of about 8.8%[41]. - The total liabilities decreased slightly to ¥4,829,659,912.81 from ¥4,832,458,153.80, indicating a marginal reduction[42]. Investments and R&D - The company reported a significant investment income of ¥1,144,264,344.36, up from ¥1,010,948,850.40, reflecting a growth of 13.2%[44]. - Research and development expenses increased to ¥59,617,581.77 from ¥46,587,670.76, representing a rise of 28.0%[44]. - The company is actively engaged in research and development of new products and technologies, although specific details were not disclosed in the report[40]. - Future outlook includes potential market expansion and strategic acquisitions to enhance growth opportunities[40]. Other Comprehensive Income - Other comprehensive income attributable to the parent company increased by 116.74% to CNY 112,765,908.41 from CNY 52,028,915.29, driven by gains from investments[36]. - Other comprehensive income after tax increased to ¥112,765,908.41 from ¥52,028,915.29, showing a growth of 116.9%[44]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 68,572, with the largest shareholder holding 28.12%[38]. - The company has a total of 327,080,749 shares held by its largest shareholder, Dunhua Jincheng Industrial Co., Ltd.[38].

| 证券代码：000623 | 证券简称：吉林敖东 | 公告编号：2023-073 | | --- | --- | --- | | 债券代码：127006 | 债券简称：敖东转债 | | 吉林敖东药业集团股份有限公司 关于控股子公司获得中药配方颗粒上市备案凭证 的自愿性信息披露公告 1 心竞争力。 未来，公司将严格遵守相关法律法规，结合市场情况开展上述产品的生产、 销售工作。但上述产品的销售情况受市场环境变化等因素的影响，具有不确定性， 预计短期内不会对公司业绩产生重大影响，敬请广大投资者谨慎决策，注意防范 投资风险。 特此公告。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，吉林敖东药业集团股份有限公司（以下简称"公司"）控股子公司吉 林敖东延边药业股份有限公司（以下简称"延边药业"）获得14个《中药配方颗 粒上市备案凭证》，现就相关情况公告如下： 根据《中华人民共和国药品管理法》《中华人民共和国药品管理法实施条例》 等法律和法规的规定，对延边药业的以下产品予以备案： | 序号 | 名称 | 备案号 | | --- | --- | --- | | 1 ...

| 证券代码：000623 | 证券简称：吉林敖东 | 公告编号：2023-072 | | --- | --- | --- | | 债券代码：127006 | 债券简称：敖东转债 | | 吉林敖东药业集团股份有限公司 股东股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东股份解除质押及质押基本情况 吉林敖东药业集团股份有限公司（以下简称"本公司"）接到股东敦化市金 诚实业有限责任公司（以下简称"金诚公司"）函告，获悉金诚公司所持有本公 司的部分股份办理解除质押手续，具体事项如下： | 股东名称 | 是否为控股股东 | 本次解除质 | 占其所 | 占公司 | 起始日 | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 或第一大股东及 | 押股份数量 | 持股份 | 总股本 | | | | | | 其一致行动人 | （万股） | 比例 | 比例 | | | | | 敦化市金诚实业 有限责任公司 | 是 | 2,000 | 6.11% | 1.72% | ...

| 证券代码：000623 | 证券简称：吉林敖东 | 公告编号：2023-071 | | --- | --- | --- | | 债券代码：127006 | 债券简称：敖东转债 | | 一、股东股份质押基本情况 吉林敖东药业集团股份有限公司（以下简称"本公司"）接到股东敦化市金 诚实业有限责任公司（以下简称"金诚公司"）函告，获悉金诚公司所持有本公 司的部分股份被质押，具体事项如下： 股东股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 吉林敖东药业集团股份有限公司 （一）股东股份质押的基本情况 | 股东名称 | 是否为控股 股东或第一 | 本次质 | 占其所持 | 占公司总 | 是否 | 是否为 | | | | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 大股东及其 | 押数量 | 股份比例 | 股本比例 | 为限 | 补充质 | 质押起始日 | 质押到期日 | 质权人 | 用途 | | | 一致行动人 | (万股) | | | 售股 ...

| 证券代码：000623 | 证券简称：吉林敖东 | 公告编号：2023-070 | | --- | --- | --- | | 债券代码：127006 | 债券简称：敖东转债 | | 吉林敖东药业集团股份有限公司 关于回购部分社会公众股份进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1 吉林敖东药业集团股份有限公司（以下简称"公司"）于2023年9月20日召 开公司第十一届董事会第三次会议、第十一届监事会第三次会议，审议通过了《关 于回购部分社会公众股份的议案》，同意以自有资金不少于人民币1.00亿元（含）， 不超过人民币1.50亿元（含）回购部分社会公众股份，回购股份全部用于员工持 股计划，回购价格不超过人民币20.00元/股。根据本次回购价格上限测算，本次 拟回购 股份 数量 上 限为 750 万股 ，即 不 超过公 司 2023 年6 月 30日总 股本 1,163,105,155股的0.64%；下限为500万股，即不低于公司2023年6月30日总股本 1,163,105,155股的0.43%。回购股份实施期限为自公司董事会审议通过本次 ...

| 证券代码：000623 | 证券简称：吉林敖东 | 公告编号：2023-069 | | --- | --- | --- | | 债券代码：127006 | 债券简称：敖东转债 | | 吉林敖东药业集团股份有限公司 2023 年第三季度可转换公司债券转股情况公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 （二）可转债上市情况 经深圳证券交易所（以下简称"深交所"）"深证上[2018]191号"文同意， 公司241,300万元可转换公司债券已于2018年5月11日起在深圳证券交易所挂牌 交易，债券简称"敖东转债"，债券代码"127006"。 1 特别提示： "敖东转债"（债券代码：127006）转股期为2018年9月19日至2024年3月 13日；转股价格现为14.21元/股。 2023年第三季度共有8,675张"敖东转债"转股，共计转换成"吉林敖东" 股票61,043股。 根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管 指引第15号——可转换公司债券》的有关规定，吉林敖东药业集团股份有限公司 （以下简称"公司"）现将2023年第三季 ...

Financial Performance - In the first half of 2023, total assets reached CNY 32,344.10 million, an increase of CNY 1,171.52 million, or 3.76% from the beginning of the year [3] - Net assets attributable to shareholders increased by CNY 874.62 million, or 3.36% [3] - The debt-to-asset ratio stood at 15.89% [3] - Operating revenue was CNY 1,583.01 million, up CNY 332.78 million, or 26.62% year-on-year [3] - Net profit attributable to shareholders was CNY 1,063.18 million, an increase of CNY 568.54 million, or 114.94% year-on-year [3] Business Segments Pharmaceutical Sector - Pharmaceutical revenue was CNY 1,159.67 million, with a gross margin of 57.52% [3] - Traditional Chinese medicine (TCM) revenue was CNY 948.13 million, up 20.47%, accounting for 59.89% of total revenue [3] - Chemical medicine revenue was CNY 211.54 million, up 39.41%, accounting for 13.36% of total revenue [3] - Chain pharmacy revenue was CNY 197.74 million, with a gross margin of 19.54% [3] - Health sector revenue was CNY 204.03 million, with a gross margin of 36.46% [3] Key Products - The core products include Anshen Bnnao Liquid, Xiaoer Chaigui Fever Oral Liquid, and Xuefu Zhuyu Oral Liquid, all showing steady sales growth [4] - Anshen Bnnao Liquid achieved sales of CNY 600 million annually, with a growth rate of 4.12% [4] - Xiaoer Chaigui Fever Oral Liquid generated CNY 112.17 million in sales, a year-on-year increase of 116.26% [4] - Brain Xinshu Oral Liquid saw a remarkable growth of 367.88%, reaching CNY 48.24 million in sales [5] Market Strategy - The company focuses on enhancing market share for core products and expanding the pediatric product line [5] - Continuous investment in R&D and academic promotion is emphasized to strengthen market presence [5] - The company aims to maintain a stable growth trajectory for key products after reaching certain sales scales [5] Investment and Financial Strategy - The financial investment segment includes investments in Guangfa Securities, contributing stable returns [8] - The company holds a 19.72% stake in Guangfa Securities, with investment returns of CNY 1.778 billion, CNY 1.958 billion, and CNY 1.448 billion from 2020 to 2022 [8] - Plans to optimize capital structure through convertible bonds, with a revised conversion price of CNY 14.50 per share [8] Future Outlook - The company is set to invest CNY 1,002.18 million in the TCM formula granule project, expected to generate CNY 1,262.64 million in sales and CNY 234.92 million in average annual profit [6] - The company is actively exploring new market strategies for chemical medicines, focusing on basic drugs and medical insurance products [6]